Purdue Pharma’s OxyContin misbranding case

Purdue Pharma’s OxyContin misbranding case concerns criminal admissions and civil penalties arising from the marketing and representation of the opioid painkiller OxyContin. The matter centers on a guilty plea by the company that produced the drug and by three current and former executives, together resolving allegations that the company had misrepresented the product’s addictive potential and risks of abuse to regulators, clinicians and patients.

According to the source excerpt, the guilty plea accompanied a payment of $600 million and formal criminal charges asserting that the company and the executives misled regulators, doctors and patients about the drug’s risk of addiction and its potential to be abused. The report also states that company sales officials were permitted to create and distribute falsified scientific charts that portrayed a lower addictive potential, and that those charts were disseminated to prescribing physicians.

This account is notable for two linked reasons in the public record presented: it documents criminal convictions by a manufacturer and individual executives for conduct about the safety and abuse potential of a prescription opioid, and it identifies specific promotional practices—namely, fabricated charts conveyed to doctors—as part of the alleged misleading conduct. The combination of a substantial financial penalty, guilty pleas, and the described misrepresentation of scientific information is the basis for the historical significance attributed to the case in the cited report.